Orthofix International ( (OFIX) ) has released its Q3 earnings. Here is a breakdown of the information Orthofix International presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Orthofix Medical Inc., headquartered in Lewisville, Texas, is a global medical technology company specializing in spinal hardware, bone growth therapies, and orthopedic solutions, with a focus on innovative technologies like the 7D FLASH™ Navigation System.
Orthofix reported a strong third quarter in 2025, with net sales reaching $205.6 million, marking a 5% increase compared to the same period in 2024. The company also adjusted its full-year sales guidance and raised the lower end of its adjusted EBITDA guidance, reflecting confidence in its financial trajectory.
Key highlights from the earnings report include an 8% growth in U.S. Spine Fixation sales and a 6% increase in Bone Growth Therapies sales. The company achieved a positive free cash flow of $2.5 million and expanded its adjusted EBITDA margin for the seventh consecutive quarter. Despite a reported net loss of $22.8 million, Orthofix’s non-GAAP pro forma adjusted EBITDA rose to $24.6 million, showcasing a 28.2% growth from the previous year.
Orthofix’s strategic initiatives, such as the successful launch of TrueLok™ Elevate and the effective cross-selling strategies in Bone Growth Therapies, have contributed to its market leadership and financial performance. The company’s disciplined investment approach and cost management have been pivotal in sustaining margin expansion and cash flow generation.
Looking ahead, Orthofix remains optimistic about its growth prospects, supported by a robust innovation pipeline and strong operational performance. The company is well-positioned to deliver lasting value to shareholders, with expectations of continued success in 2025 and beyond.